• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xencor, Inc. - Common Stock (NQ:XNCR)

23.34 +0.35 (+1.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 443,072
Open 22.91
Bid (Size) 19.50 (500)
Ask (Size) 24.00 (100)
Prev. Close 22.99
Today's Range 22.50 - 23.45
52wk Range 7.130 - 23.45
Shares Outstanding 59,924,016
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Xencor (NASDAQ:XNCR) Beats Q2 Estimates on Royalty Settlement and Milestone Payment ↗
August 05, 2026
Via Chartmill
News headline image
Xencor Reports Second Quarter 2026 Financial Results
August 05, 2026
From Xencor, Inc.
Via Business Wire

Performance

YTD
+56.4%
+56.4%
1 Month
+56.1%
+56.1%
3 Month
+111.0%
+111.0%
6 Month
+102.3%
+102.3%
1 Year
+203.9%
+203.9%

More News

Read More
News headline image
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
July 29, 2026
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
July 17, 2026
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Reports First Quarter 2026 Financial Results
May 06, 2026
From Xencor, Inc.
Via Business Wire
News headline image
Beyond The Numbers: 4 Analysts Discuss Xencor Stock ↗
September 02, 2025
Via Benzinga
News headline image
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
May 04, 2026
From Xencor, Inc.
Via Business Wire
Curious about the stocks that are showing activity after the closing bell on Friday? ↗
April 03, 2026
Via Chartmill
Top movers in Tuesday's after hours session ↗
March 31, 2026
Via Chartmill
News headline image
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast
March 04, 2026
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results
February 25, 2026
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Participate at Upcoming Investor Conferences
February 23, 2026
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones
January 08, 2026
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies
December 09, 2025
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Participate at Upcoming Investor Conferences
November 10, 2025
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Reports Third Quarter 2025 Financial Results
November 05, 2025
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
October 24, 2025
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
October 21, 2025
From Xencor, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
October 14, 2025
Via Benzinga
News headline image
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 14, 2025
From Xencor, Inc.
Via Business Wire
News headline image
Xencor to Participate at Upcoming Investor Conferences
August 27, 2025
From Xencor, Inc.
Via Business Wire
News headline image
Xencor (XNCR) Q2 Revenue Jumps 82% ↗
August 06, 2025
Via The Motley Fool
Topics Intellectual Property
News headline image
Xencor Reports Second Quarter 2025 Financial Results
August 06, 2025
From Xencor, Inc.
Via Business Wire
News headline image
Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors
July 31, 2025
From Xencor, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
May 09, 2025
Via Benzinga

Frequently Asked Questions

Is Xencor, Inc. - Common Stock publicly traded?
Yes, Xencor, Inc. - Common Stock is publicly traded.
What exchange does Xencor, Inc. - Common Stock trade on?
Xencor, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Xencor, Inc. - Common Stock?
The ticker symbol for Xencor, Inc. - Common Stock is XNCR on the Nasdaq Stock Market
What is the current price of Xencor, Inc. - Common Stock?
The current price of Xencor, Inc. - Common Stock is 23.34
When was Xencor, Inc. - Common Stock last traded?
The last trade of Xencor, Inc. - Common Stock was at 08/14/26 04:00 PM ET
What is the market capitalization of Xencor, Inc. - Common Stock?
The market capitalization of Xencor, Inc. - Common Stock is 1.40B
How many shares of Xencor, Inc. - Common Stock are outstanding?
Xencor, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap